A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer

Cancer

Volumn 113, Issue 9, 2008, Pages 2532-2538

  Cassier, Philippe A ^a   Ray Coquard, Isabelle ^b   Sunyach, Marie Pierre ^b   Lancry, Laurence ^b   Guastalla, Jean Paul ^b   Ferlay, Céline ^b   Gomez, Frédéric ^b   Curé, Hervé ^c   Lortholary, Alain ^d   Claude, Line ^b   Blay, Jean Yves ^a   Bachelot, Thomas ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE JEAN PERRIN   (France)

^d Centre Catherine de Sienne   (France)

Author keywords

Brain metastases; Breast cancer; Chemoradiation; Cisplatin; Vinorelbine; Whole brain radiation therapy

Indexed keywords

CISPLATIN; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; VINBLASTINE;

EID: 55549128225     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23858     Document Type: Article

References (28)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608-3617.
2. Bartsch R, Fromm S, Rudas M, et al. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol. 2006;80:313-317.
3. DiStefano A, Yong YY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44:1913-1918.
4. Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62:211-216.
5. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500.
6. Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer. 2004;100:1705-1711.
7. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599-1605.
8. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol. 2005;71:61-65.
9. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69:972-980.
10. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-5917.
11. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
12. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
14. Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest. 1990;8:327-334.
15. Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982;42:2474-2479.
16. Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol. 1988;11:152-158.
17. Ray-Coquard I, Biron P, Bachelot T, et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998;82: 134-140.
18. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59-67.
19. Lancry L, Ray-Coquard I, Gorain C, et al. A phase II trial of whole brain radiotherapy and concomitant cisplatinum and vinorelbine for breast cancer patients with brain metastases. Breast Cancer Res Treat. 2004;88:S170.
20. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346-353.
21. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
23. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in 3 Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
24. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;20:1993-1999.
25. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15:1042-1047.
26. Gruschow K, Klautke G, Fietkau R. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur J Cancer. 2002;38:367-374.
27. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644-3650.
28. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107:1348-1354.